Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gregan YI"'
Autor:
Aranow C; Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA caranow@northwell.edu., Allaart CF; Leids Universitair Medisch Centrum, Leiden, The Netherlands., Amoura Z; Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Paris, France., Bruce IN; Kellgren Centre for Rheumatology, Manchester University Hospitals NHS Trust, Manchester, UK.; Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Cagnoli PC; University of Michigan Medical Center, Ann Arbor, Michigan, USA., Chatham WW; University of Alabama at Birmingham, Birmingham, Alabama, USA., Clark KL; Clinical Science, GSK, Stevenage, UK., Furie R; Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA., Groark J; Clinical Development, GSK, Collegeville, Pennsylvania, USA., Urowitz MB; Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, Ontario, Canada., van Vollenhoven R; Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, The Netherlands., Daniels M; Global Medical Affairs, GSK, Brentford, UK., Fox NL; Clinical Development, GSK, Collegeville, Pennsylvania, USA., Gregan YI; Clinical Science Immunology, GSK, Collegeville, Pennsylvania, USA., Henderson RB; Clinical Biomarker Group, GSK, Stevenage, UK., van Maurik A; Clinical Biomarker Group, GSK, Stevenage, UK., Ocran-Appiah JC; Clinical Science, Respiratory and Immunology Clinical Research and Early Programs, GSK, Philadelphia, Pennsylvania, USA., Oldham M; Biostatistics, GSK, Stevenage, UK., Roth DA; Research and Development, GSK, Collegeville, Pennsylvania, USA., Shanahan D; Development Biostatistics, GSK, GSK House, Brentford, UK., Tak PP; Research and Development, GSK, Stevenage, UK., Teng YO; Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Publikováno v:
Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Oct 21; Vol. 83 (11), pp. 1502-1512. Date of Electronic Publication: 2024 Oct 21.
Autor:
Arends EJ; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Zlei M; Department of Immunology, Leiden University Medical Centre, Leiden, The Netherlands.; Medical Laboratory, Department of Flow Cytometry, Regional Institute of Oncology, Iasi, Romania., Tipton CM; Lowance Centre for Human Immunology, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, USA., Cotic J; Clinical Statistics, GSK, Middlesex, UK., Osmani Z; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., de Bie FJ; Department of Immunology, Leiden University Medical Centre, Leiden, The Netherlands., Kamerling SWA; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., van Maurik A; Clinical Pharmacology and Experimental Medicine, GSK, Hertfordshire, UK., Dimelow R; Clinical Pharmacology Modelling and Simulation, GSK, Hertfordshire, UK., Gregan YI; Clinical Science Immunology, GSK, Collegeville, PA, USA., Fox NL; Clinical Development, GSK, Collegeville, PA, USA., Rabelink TJ; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Roth DA; Research and Development, GSK, Collegeville, PA, USA., Sanz I; Lowance Centre for Human Immunology, Emory University School of Medicine, Atlanta, GA, USA., van Dongen JJM; Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., van Kooten C; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Teng YKO; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.
Publikováno v:
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Sep 01; Vol. 63 (9), pp. 2387-2398.
Autor:
Hunnicutt JN; Value Evidence and Outcomes, GSK, Collegeville, Pennsylvania, USA jacob.n.hunnicutt@gsk.com., Fairburn-Beech J; Value Evidence and Outcomes, GSK, Brentford, UK., Georgiou ME; Value Evidence and Outcomes, GSK, Brentford, UK., Richards A; Value Evidence and Outcomes, GSK, Brentford, UK., Gregan YI; Clinical Science Immunology, GSK, Collegeville, Pennsylvania, USA., Quasny H; Research and Development, GSK, Durham, North Carolina, USA., Chauhan D; Value Evidence and Outcomes, GSK, Brentford, UK.
Publikováno v:
Lupus science & medicine [Lupus Sci Med] 2022 Nov; Vol. 9 (1).